Entrada Therapeutics, Inc. (TRDA) Financials

TRDA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 335.5 million 64.7 million
Dec. 31, 2025 377.4 million 71.2 million
Sept. 30, 2025 412.9 million 72.2 million
June 30, 2025 448.8 million 69.3 million

TRDA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -41.7 million ?
Dec. 31, 2025 -32.0 million 4.4 million
Sept. 30, 2025 -28.1 million 5.1 million
June 30, 2025 -29.8 million 5.0 million

TRDA Net Income

No data available :(

TRDA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 254.9 million 45.5 million -
Dec. 31, 2025 295.7 million 46.8 million 50.9 million
Sept. 30, 2025 326.8 million - 48.1 million
June 30, 2025 354.0 million - 54.7 million

TRDA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 41.8 million
Dec. 31, 2025 41.4 million
Sept. 30, 2025 41.5 million
June 30, 2025 41.3 million

TRDA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 44000 33.1 million 10.1 million -
Dec. 31, 2025 207000 34.0 million 9.6 million -
Sept. 30, 2025 171000 38.4 million 10.3 million -
June 30, 2025 275000 37.9 million 10.9 million -

TRDA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 875000 805000
Dec. 31, 2025 1.3 million 886000
Sept. 30, 2025 1.6 million 38.4 million
June 30, 2025 2.0 million 1.1 million

TRDA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

TRDA

Price: $6.58

52 week price:
4.93
16.45

Earnings Per Share: -4.00 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 22900

Market Capitalization: 268.4 million

Links: